# Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer

> **NCT07569679** · PHASE2 · RECRUITING · sponsor: **Air Force Military Medical University, China** · enrollment: 124 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **PROCEDURE:** HAIC
- **DRUG:** Gemcitabine plus Cisplatin
- **DRUG:** Adebrelimab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT07569679
- **Lead sponsor:** Air Force Military Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-10
- **Primary completion:** 2028-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07569679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07569679, "Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07569679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*